Table 1 Patient characteristics.

Recipient characteristics

 Age (years, median)

55.5 (48.8–61.3)

54.4 (45.8–64.7)

0.742

 Sex (n, % male)

1846 (69.6)

11 (61.1)

0.6

 Weight (kg, median)

65.1 (56.5–73.8)

64.1 (56.0–71.3)

0.666

 BMI (kg/m², median)

23.6 (21.3–26.3)

23.3 (21.1–27.3)

0.828

 Etiology (n, %)

0.438

  HBV

1312 (49.5)

6 (33.3)

  HCV

156 (5.9)

1 (5.6)

  Alcoholic

682 (25.7)

6 (33.3)

  Cryptogenic

163 (6.1)

2 (11.1)

  Autoimmune

71 (2.7)

0 (0.0)

  PBC/PSC/SSC

54 (2.0)

0 (0.0)

  Congenital bile duct disorder

81 (3.1)

1 (5.6)

  Other

133 (5.0)

2 (11.1)

 Liver cancer (n, %)

0.725

  HCC

1302 (49.1)

10 (55.6)

  CCC

8 (0.3)

0 (0.0)

  HCC & CCC

25 (0.9)

0 (0.0)

  Other malignancy

4 (0.2)

0 (0.0)

 Reason for primary LT

1.000

  Acute liver failure

114 (4.3)

0 (0.0)

  Acute on chronic liver failure

123 (4.6)

0 (0.0)

  Liver cirrhosis

1076 (40.6)

8 (44.4)

  Liver cancer

1339 (50.5)

10 (55.6)

 Era of LT

0.260

  2014–2016

933 (35.2)

3 (16.7)

  2017–2018

799 (30.1)

7 (38.9)

  2019–2020

920 (34.7)

8 (44.4)

  3.2 (2.8–3.7)

3.0 (2.6–3.6)

0.254

 Pre-transplant Total bilirubin (mg/dL, median)

2.2 (1.0–8.0)

1.9 (0.9–3.2)

0.491

 Pre-transplant INR (median)

1.39 (1.15–1.95)

1.45 (1.20–1.97)

0.706

 Pre-transplant Creatinine (mg/dL, median)

0.81 (0.64–1.07)

0.82 (0.62–1.00)

0.55

 Ascites (n, %)

0.869

  None

1020 (38.5)

8 (44.4)

  Mild (diuretic responsive)

844 (31.8)

5 (27.8)

  Moderate to severe (diuretic refractory)

788 (29.7)

5 (27.8)

 Hepatic encephalopathy (n, %)

0.838

  None

2038 (76.8)

15 (83.3)

  Grade I–II

456 (17.2)

3 (16.7)

  Grade III–IV

158 (6.0)

0 (0.0)

 Child-Turcotte-Pugh (CTP) class (n, %)

0.455

  A

792 (29.9)

5 (27.8)

  B

830 (31.3)

8 (44.4)

  C

1030 (38.8)

5 (27.8)

 CTP score (median)

8 (6–11)

8.5 (6–10)

0.637

 MELD score (median)

14 (9–24)

12 (9–16.5)

0.335

 Re-LT (n, %)

1

  2nd re-LT

41 (1.5)

0 (0.0)

  3rd re-LT

5 (0.2)

0 (0.0)

 LT type (n, %)

0.011

  Living donor

1991 (75.1)

18 (100.0)

  Deceased donor

661 (24.9)

0 (0.0)

 Donor characteristics

  Age (years, median)

36.4 (26.3–48.7)

32.6 (23.9–38.9)

0.027

  Sex (n, % male)

1604 (60.5)

9 (50.0)

0.506

 Relationship (n, %)

0.002

  Parent

84 (3.2)

2 (11.1)

  Offspring

1266 (47.7)

15 (83.3)

  Sibling

199 (7.5)

0 (0.0)

  Spouse

277 (10.4)

0 (0.0)

  Relatives in blood

143 (5.4)

1 (5.6)

  Other relationships

683 (25.8)

0 (0.0)

  Graft weight (g, median)

710 (612–816)

764 (606–876)

0.383

  GRWR (%, median)

1.09 (0.93–1.30)

1.18 (1.02–1.53)

0.093

 Graft type (n, %)

0.045

  Right lobe

1730 (65.2)

15 (83.3)

  Extended Right lobe

130 (4.9)

1 (5.6)

  Extended Left lobe

30 (1.1)

1 (5.6)

  Left lobe

58 (2.2)

0 (0.0)

  Left lateral section

59 (2.2)

1 (5.6)

  Whole liver

613 (23.1)

0 (0.0)

  Others

32 (1.2)

0 (0.0)

 Post-transplant outcome

  Warm ischemic time (min, median)

35.5 (27.0–49.0)

50.0 (36.5–61.0)

0.025

  Cold ischemic time (hours, median)

1.9 (1.3–3.0)

1.9 (1.2–2.5)

0.615

  GVHD (n, %)

7 (0.3)

4 (22.2)

 < 0.001

  Graft failure (n, %)

106 (4.0)

1 (5.6)

0.522

 Biopsy proven Rejection (n, %)

0.353

  Acute T-cell mediated rejection

267 (10.1)

0 (0.0)

  Acute antibody mediated rejection

13 (0.5)

0 (0.0)

  Chronic rejection

11 (0.4)

0 (0.0)

  Follow up period (years, median)

2.00 (0.49–4.00)

0.95 (0.25, 2.25)

0.060

  Death (n, %)

307 (11.6)

7 (38.9)

0.003

 Cause of death (n, %)

0.024

  Cardiovascular disease

22 (7.2)

0 (0.0)

  Infection

126 (41.0)

2 (28.6)

  Liver failure

70 (22.8)

2 (28.6)

  Recurred HCC

45 (14.7)

1 (14.3)

  Malignancy except HCC

3 (1.0)

0 (0.0)

  GVHD

3(1.0)

2 (28.6)

  Others

38 (12.4)

0 (0.0)